Compass Therapeutics (CMPX) | Stock Overview & Key Data
Compass Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $11.00 on April 12, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Compass Therapeutics
CMPX
|
905.84M Small-cap | -7.49% | 8.25% | -62.03% | -60.23% | -59.38% | 13.33% | -19.05% | -55.93% | -72.00% | -72.00% | -72.00% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Zymeworks
ZYME
|
1.96B Small-cap | -1.77% | -9.07% | -0.41% | -7.13% | -8.53% | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
|
Amylyx
AMLX
|
1.91B Small-cap | -6.18% | -19.81% | -6.45% | -7.11% | 15.59% | 178.64% | -43.01% | -20.59% | -20.59% | -20.59% | -20.59% |
|
Syndax
SNDX
|
1.89B Small-cap | -6.48% | -8.12% | -14.30% | -6.95% | -13.90% | 85.86% | -4.30% | 9.75% | 48.41% | 65.32% | 65.32% |
Ownership & Short Interest
Calculate Your Compass Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Compass Therapeutics stock price in Apr 2021 was $8.50, A $1,000.00 lump sum investment in Compass Therapeutics made 5 years ago would be worth approximately $247.06 today, representing a negative return of -75.29%. This translates to an annualized return (CAGR) of -23.73%.
5 Years 1 Month Investment Scenario (Apr 2021 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is CMPX's 52-week high and low?
- In the last 52 weeks, Compass Therapeutics reached a high of $6.88 (on February 3, 2026) and a low of $1.61 (on N/A).
- What is the market cap and P/E ratio for CMPX?
- Curious about Compass Therapeutics's size and valuation? Its market capitalization stands at 905.84M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -10.42.
- Does CMPX pay dividends? If so, what's the yield?
- As for dividends, Compass Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Compass Therapeutics's main competitors or similar companies to consider before investing?
When looking at Compass Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Zymeworks
ZYME1.96B Healthcare Biotechnology 119.86% 189.85% Amylyx
AMLX1.91B Healthcare Biotechnology 178.64% -43.01% Syndax
SNDX1.89B Healthcare Biotechnology 85.86% -4.30% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Compass Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Compass Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -41.29%, the Debt to Equity ratio from the most recent quarter is 5.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CMPX?
- Looking at Compass Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of CMPX stock is held by insiders and institutions?
- Wondering who owns Compass Therapeutics stock? Company insiders (like executives and directors) hold about 11.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 88.07%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.